Document:

Exhibit 10.52

 

ANDA SECURITY AGREEMENT

 

THIS ABBREVIATED NEW DRUG APPLICATION
SECURITY AGREEMENT (the “Agreement”), dated as of May 15, 2017, between Elite Laboratories, Inc.,
a Delaware corporation (“Elite”) and its parent, Elite Pharmaceuticals, Inc., a Nevada corporation (collectively,
“Debtors”), and Mikah Pharma LLC, a limited liability company organized under the laws of the State of
Delaware ("Secured Party");

 

WHEREAS, Debtors and Secured Party
are parties to that certain Secured Note Due 2020 of even date herewith (herein, as at any time amended, extended, restated, renewed
or modified, the "Note"); and

 

WHEREAS, it is a condition to the
willingness of Secured Party to enter into the Asset Purchase Agreement by and between Secured Party and Elite of even date (the
“Purchase Agreement”), to sell the Purchased Assets (as defined in the Purchase Agreement) to Elite and
to accept the Note as consideration under the Purchase Agreement for the Purchased Assets that Debtors enter into this ANDA Security
Agreement and grant to Secured Party the security interest provided for herein; and

 

WHEREAS, in order to induce Secured
Party to accept the Note and the debt evidenced thereby as consideration for the Purchased Assets under the Purchase Agreement,
Debtors have agreed to grant to Secured Party a security interest in and to and mortgage on the Abbreviated New Drug Applications
included in the Purchased Assets (collectively, the "ANDAs"). This Agreement is being executed contemporaneous
with the Purchase Agreement and the Note under which Secured Party is granted a lien on and security interest in and to, the ANDAs,
whereby Secured Party shall have the right to foreclose on the ANDAs in the event Secured Party alleges the occurrence of an Event
of Default under the Note. Terms not defined herein shall have the meaning set forth in the Note and terms not defined herein or
in the Note shall have the meaning set forth in the Purchase Agreement.

 

NOW, THEREFORE, in consideration
of the premises, and other good and valuable consideration the sufficiency of which is hereby acknowledged, Debtors hereby agree
with Secured Party as follows:

 

1. To secure any and all obligations of
Debtors to Secured Party under the Note and Transaction Documents, including but not limited to, repayment of the obligations of
Debtors under the Note, Debtors hereby convey, grant, assign, pledge, transfer, mortgage, and create in favor of Secured Party
a security interest in and to and mortgage on all of Debtors’ right, title and interest in and to the Purchased Assets (as
that term is defined in the Purchase Agreement), including without limitation any and all rights under any notices or agreements
related thereto (collectively, the “Collateral”).

 

     

     

    

 

2. Debtors represent, covenant and warrant
that, subject to the representations of the Secured Party in the Purchase Agreement:

 

(a) the ANDAs are subsisting;

 

(b) Elite is the sole and exclusive owner
of the entire and unencumbered right, title and interest in and to the Collateral, free and clear of any liens, charges and encumbrances,
including without limitation pledges, assignments, registered user agreements and covenants by Debtors not to sue third persons;

 

(c) Debtors have the unqualified right
to enter into this Agreement and perform its terms; and

 

(d) All ANDAs on file with the Food and
Drug Administration (the "FDA") were prepared in accordance with applicable law.

 

3. Debtors agree that, until all of the
obligations under the Note shall have been satisfied in full, Debtors will not, without Secured Party's prior written consent,
which consent will not be unreasonably withheld, enter into any agreement to transfer or sell any of the Collateral.

 

3A. Perfection of Secured Party’s
Interests.

 

(a) Debtors agree to cooperate and join,
at their expense, with Secured Party in taking such steps as are reasonably necessary, in Secured Party’s judgment, to perfect
or continue the perfected status of the security interests granted hereunder, including, without limitation, the execution and
delivery of any financing statements, amendments thereto and continuation statements, the delivery of chattel paper, documents
or instruments to the Secured Party, the obtaining of landlords’ and mortgagees’ waivers required by Secured Party,
the notation of encumbrances in favor of Secured Party on certificates of title, and the execution and filing of any collateral
assignments and any other instruments reasonably requested by Secured Party to perfect its security interest in any and all of
the Collateral.

 

(b) Secured Party may at any time and from
time to time, file financing statements, continuation statements, filings with the FDA or other federal agencies, and amendments
thereto, that describe the Collateral and which contain any other information required by the Uniform Commercial Code or federal
law for the sufficiency or filing office acceptance of any financing statement, continuation statement, other filing, or amendment,
including whether a Debtor is an organization, the type of organization and any organization identification number issued to the
Debtor. Debtors agree to furnish any such information to the Secured Party promptly upon request. Any such financing statements,
continuation statements, other filing or amendments may be signed by Secured Party on behalf of Debtors, and may be filed at any
time in any jurisdiction, whether or not Revised Article 9 of the Uniform Commercial Code is then in effect in that jurisdiction.
The foregoing grant of authority to sign and file such documents on behalf of Debtors is a power of attorney coupled with an interest
and shall be irrevocable for the life of this Agreement. Secured Party, or its designee, as attorney-in-fact, will not be liable
for any acts or omissions, or for any error of judgment or mistake of fact or law, except for gross negligence, or willful misconduct.
This power, being coupled with an interest, is irrevocable until all obligations of Debtors to Secured Party under the Note and
Transaction Documents have been indefeasibly paid in full and performed and satisfied.

 

    	 	2	 

     

    

 

(c) Debtors shall, at any time and from
time to time, take such steps as Secured Party may reasonably require for Secured Party, (i) to obtain an acknowledgment, in form
and substance satisfactory to the Secured Party, of any third party having possession of any of the Collateral that the third party
holds such Collateral for the benefit of the Secured Party, and (ii) otherwise to insure the continued perfection and priority
of Secured Party’s security interest in any of the Collateral and of the preservation of its rights therein.

 

4. If any Event of Default under the Note
or this Agreement shall have occurred, Secured Party shall have, in addition to all other rights and remedies given it by this
Agreement, those allowed by law and the rights and remedies of a Secured Party under the Uniform Commercial Code as enacted in
any jurisdiction in which the ANDAs may be deemed located and, without limiting the generality of the foregoing, Secured Party
may immediately, without demand of performance and without notice or demand whatsoever to Debtor, all of which are hereby expressly
waived, and without advertisement, sell at public or private sale or otherwise realize upon, assign, transfer, license or otherwise
dispose of, including but not limited to, transferring the ANDAs in New Jersey or elsewhere, all or from time to time any of the
ANDAs, or any interest which Debtors may have therein, and after deducting from the proceeds of sale or other disposition of any
and all of the ANDAs all expenses (including all expenses for broker's fees and legal services), apply the residue of such proceeds
to Debtors’ obligations to Secured Party under the Note. Any remainder of the proceeds after payment in full of Debtors’
obligations owing to Secured Party under the Note and Transaction Documents including but not limited to the repayment in full
of Debtors’ obligations to Secured Party under the Note shall be paid over to Debtor. Notice of any sale or other disposition
of the ANDAs shall be given to Debtors at least ten (10) days before the time of any intended public or private sale or other disposition
of the ANDAs is to be made, which Debtors hereby agree shall be reasonable notice of such sale or other disposition. At any such
sale or other disposition, Secured Party or any holder of the Note may, to the extent permissible under applicable law, purchase
the whole or any part of the ANDAs free from any right of redemption on the part of Debtors, which right is hereby waived and released.
Debtors waive the benefit of any marshalling doctrine with respect to Secured Party’s exercise of its rights hereunder. Debtors
grant a royalty-free license to Secured Party for all patents, service marks, trademarks, trade names, copyrights, computer programs
and other intellectual property and proprietary rights sufficient to permit Secured Party to exercise all rights granted to Secured
Party under this Agreement.

 

5. At such time as Debtors shall completely
satisfy all of Debtors’ obligations to Secured Party under the Note and Transaction Documents including but not limited to
repayment of the obligations of Debtors under the Note, this Agreement and the Note shall terminate and Secured Party shall execute
and deliver to Debtors all documents and other instruments as may be necessary or proper to terminate this Agreement and re-vest
in Elite the ANDAs, subject to any disposition thereof which may have been made by Secured Party pursuant hereto.

 

    	 	3	 

     

    

 

6. Any and all fees, costs and expenses,
of whatever kind or nature, including reasonable attorney's fees and legal expenses incurred by Secured Party in connection with
the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in
public offices, the payment or discharge of any taxes, counsel fees, maintenance fees, encumbrances or otherwise protecting, maintaining
or preserving the ANDAs, or in defending or prosecuting any actions or proceedings arising out of or related to the ANDAs, shall
be borne and paid by Debtors on demand by Secured Party and until so paid shall become part of Debtors’ obligations under
the Note. Debtors hereby agree to execute and deliver to Secured Party any and all additional documents requested by Secured Party
regarding the ANDAs at any time and from time to time in its discretion to carry out and enforce the terms and conditions of this
Agreement.

 

7. Debtors shall have the duty, through
counsel acceptable to Secured Party, to complete the approval process of the ANDAs, pending as of the date of this Agreement or
thereafter until all of Debtors’ obligations under the Note shall have been paid in full, to file and provide further information
and documentation and to do any and all acts which are necessary or desirable to seek approval of the ANDAs and to preserve and
maintain all rights to the ANDAs. Any expenses incurred in connection with the ANDAs shall be borne by Debtors. Debtors shall not
abandon any ANDAs without the consent of Secured Party, which consent shall not be unreasonably withheld.

 

8. If Debtors breach or fail to comply
with any of the terms and conditions of this Agreement or upon the occurrence of an Event of Default under the Note or any of the
Transaction Documents, Debtors hereby authorize and empower Secured Party to make, constitute and appoint any officer or agent
of Secured Party as Secured Party may select, in its exclusive discretion, as Debtors’ true and lawful attorney-in-fact,
with the power to endorse Debtors’ name on all applications, documents, papers and instruments of every kind and nature necessary
or desirable, including without limitation, for Secured Party to approve, use, own, transfer, assign, license or dispose of the
ANDAs, or necessary or desirable for Secured Party to assign, pledge, convey or otherwise transfer title in or dispose of the ANDAs
to Secured Party or anyone else, including without limitation any and all Forms 356H, and/or such other forms as the FDA shall
require. Debtors hereby ratify all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney
shall be irrevocable for the life of this Agreement. Secured Party, or its designee, as attorney-in-fact, will not be liable for
any acts or omissions, or for any error of judgment or mistake of fact or law, except for gross negligence, or willful misconduct.
This power, being coupled with an interest, is irrevocable until all obligations of Debtors to Secured Party under the Note and
Transaction Documents have been indefeasibly paid in full and performed and satisfied.

 

9. If Debtors fail to comply with any of
their obligations hereunder, Secured Party may do so in Debtors’ name or in Secured Party's name, but at Debtors’ expense,
and Debtors hereby agree to reimburse Secured Party in full for all expenses, including reasonable attorney's fees, incurred by
Secured Party in approving, protecting, defending and maintaining the ANDAs.

 

10. No course of dealing between Debtors
and Secured Party, nor any failure to exercise, nor any delay in exercising, on the part of Secured Party, any right power or privilege
hereunder or under the Note shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or
privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

 

    	 	4	 

     

    

 

11. All of Secured Party's rights and remedies
with respect to the ANDAs, whether established hereby or by the Note or the other Transaction Documents, or by any other agreements
or by law shall be cumulative and may be exercised singularly or concurrently.

 

12. The provisions of this Agreement are
severable, and if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then
such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such jurisdiction, and shall
not in any manner affect such clause or provision in any other jurisdiction, or any other

clause or provision of this Agreement in
any jurisdiction.

 

13. This Agreement is subject to modification
only by a writing signed by the parties.

 

14. The benefits and burdens of this Agreement
shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties.

 

15. The validity and interpretation of
this Agreement and the rights and obligations of the parties shall be governed by the laws of the State of New Jersey.

 

16. The provisions of Sections 13 and 14
of the Note are hereby incorporated by reference into this Agreement. To the extent that there is a conflict between the provisions
of this Agreement and Sections 13 and 14 of the Note, the provisions of this Agreement shall govern.

 

[Signature Page follows]

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF, this ANDA Security
Agreement is execution hereof as of the day and year first above written.

 

	Debtors:	 
	 	 
	 	ELITE LABORATORIES, INC.	ELITE PHARMACEUTICALS, INC.
	 	 	 	 
	By:	/s/ Carter Ward	By:	/s/ Carter Ward
	Name:	Carter Ward	Name:	Carter Ward
	Title:	CFO	Title:	CFO

 

	Secured Party:	 
	 	 	 
	 	MIKAH PHARMA LLC	 
	 	 	 
	By:	/s/ Nasrat Hakim	 
	 	Nasrat Hakim	 
	 	Title:  CEO	 

 

    	 	6	 

     

    

 

STATE OF NEW JERSEY )

) ss.:

COUNTY OF                              
  )

 

On the               day of May, in the year
2017, before me personally came                              , to me known, who, being by me duly sworn, did depose and say that he resides in                                                                                    ;
that he is the                                of Elite Laboratories, Inc., the corporation described in and which executed the above instrument; and
that he signed his name thereto by authority of the board of directors of said corporation.

 

                                             

Notary Public

 

STATE OF NEW JERSEY )

) ss.:

COUNTY OF                               )

 

On the                    day of May, in the year
2017, before me personally came                          , to me known, who, being by me duly sworn, did depose and say that he resides in                                                                           ;
that he is the                             of Elite Pharmaceuticals, Inc., the corporation described in and which executed the above instrument;
and that he signed his name thereto by authority of the board of directors of said corporation.

 

                                    

Notary Public

 

STATE OF NEW JERSEY )

) ss.:

COUNTY OF                                     )

 

On the                            
day of May, in the year 2017, before me personally came Nasrat Hakim, to me known, who, being by me duly sworn, did depose
and say that he resides in                                                                            ;
that he is the                        of Mikah Pharma LLC., the limited liability company described in and which executed the above instrument;
and that he signed his name thereto upon his authority as manager of said company.

 

                                               

Notary Public

 

    	 	7	 

     

    

 

SPECIAL POWER OF ATTORNEY

 

STATE OF NEW JERSEY)

) ss.:

COUNTY OF                                   )

 

KNOW ALL MEN BY THESE PRESENTS,
that Elite Laboratories, Inc., a Delaware corporation, having an address at 165 Ludlow Avenue, Northvale, New Jersey 07647 ("Debtor"),
pursuant and subject to the terms and conditions contained in an Abbreviated New Drug Application Security Agreement dated as of
the date hereof (as amended, modified, restated or supplemented from time to time, the "Security Agreement"),
hereby appoints and constitutes Mikah Pharma LLC with an address at 20 Kilmer Drive, Hillsborough, New Jersey, 08844 ("Secured
Party"), its true and lawful attorney, with full power of substitution, and with full power and authority to perform the
following acts on behalf of Debtor:

 

1. Assigning, selling, transferring, or
otherwise disposing of all right, title and interest of Debtor in and to all Abbreviated New Drug Applications ("ANDA")
of Debtor specified in the Security Agreement, and all registrations and recordings thereof, and all pending applications therefor,
and for the purpose of the recording, registering and filing of, or accomplishing any other formality with respect to, the foregoing,
and to execute and deliver any and all agreements, documents, instruments of assignment or other writings necessary or advisable
to effect such purpose;

 

2. To execute any and all documents, statements,
certificates or other writings necessary or advisable in order to effect the purposes described above as Secured Party may in its
sole discretion determine including without limitation any and all Forms 356H and/or such other forms as the FDA may require.

 

This power of attorney is made pursuant
to the Security Agreement, dated the date hereof, between Debtor and Secured Party and may not be revoked until the payment in
full of all Debtors’ obligations under the Security Agreement.

 

	 	 	 	ELITE LABORATORIES, INC.
	 	 	 	 
	ATTEST:	 	 	 
	 	 	By:	 
	 	 	 	Name:
	 	 	 	Title:
	 	 	 	 
	 	 	 	 
	Name:	 	 	 
	Title:	 	 	 

 

    	 	8	 

     

    

 

STATE OF NEW JERSEY )

) ss.:

COUNTY OF                                     )

 

On the                     day of May, in the year
2017, before me personally came                            , to me known, who, being by me duly sworn, did depose and say that he resides in                                                                                        ;
that he is the                        of Elite Laboratories, Inc., the corporation described in and which executed the above instrument; and
that he signed his name thereto by authority of the board of directors of said corporation.

 

                                                 

Notary Public

 

    	 	9Exhibit
10.53

 

ASSIGNMENT AGREEMENT

 

This assignment agreement ( “Assignment
Agreement”) is entered into as of May 17, 2017, by and between Mikah Pharma LLC (“Mikah”) organized and existing
under the laws of Delaware having an office at 20 Kilmer Drive, Hillsborough, NJ 08844 (the “Mikah”), and Elite Laboratories,
Inc. (“Elite”) organized and existing under the laws of Delaware having an office at 165 Ludlow Avenue, Northvale,
NJ 07647. Capitalized terms used but not defined herein shall have the meanings ascribed to them in that certain Supply and Distribution
Agreement between Mikah Pharma LLC and Dr. Reddy’s Laboratories, Inc. at 107 College Road East, Princeton, NJ 08540 dated
as of May 4, 2017 (the “Distribution Agreement”).

 

WHEREAS, Dr. Reddy and Mikah Mikah entered
into the Distribution Agreement for sales and distribution of the Product;

 

WHEREAS, on May 16, 2017, Mikah sold all
of its rights, interests and obligations to Elite for the Product in the Distribution Agreement.

 

WHEREAS, under Section 13.8 of the Distribution
Agreement, the Mikah wishes to transfer and assign to the Elite all of the Mikah’s rights and interests in and to, and obligations
under the Distribution Agreement, and the Elite wishes to be the Elite and transferee of such rights, interests and obligations;

 

NOW, THEREFORE, the parties hereto, intending
to be legally bound, do hereby agree as follows:

 

1. Assignment and Assumption. The Mikah
hereby transfers and assigns to the Elite, and the Elite hereby acquires from the Mikah all of the Mikah’s rights, and interests
in and to the Distribution Agreement, of whatever kind or nature, and the Elite hereby assumes and agrees to perform all obligations,
duties, liabilities and commitments of the Mikah under the Distribution Agreement, of whatever kind or nature.

 

3. Effectiveness. This Assignment Agreement
shall be effective as of the date set first set forth above.

 

4. Governing Law; Binding Effect. This
Assignment Agreement shall be governed in accordance with the substantive laws of the State of New Jersey, United States without
giving effect to that State’s rules on conflicts of law, and any litigation that may arise herefrom shall be instituted in
any U.S. Federal Court that has jurisdiction.

 

5. Counterparts. This Assignment Agreement
may be executed in one or more counterparts, including facsimile counterparts, each of which shall be deemed to be an original
copy of this Assignment Agreement, and all of which, when taken together, shall be deemed to constitute one and the same agreement.
Delivery of such counterparts by facsimile or electronic mail (in PDF or .tiff format) shall be deemed effective as manual delivery.

 

     

     

    

 

IN WITNESS WHEREOF, the Elite and
Mikah have executed this Assignment Agreement as of the date first set forth above.

 

	:	 
	ELITE LABORATORIES, INC.	 
	By:	/s/ Carter Ward	 
	 	 	 
	Name: 	Carter Ward	 
	 	 	 
	Title: 	CFO	 
	 	 
	:	 
	MIKAH PHARMA LLC	 
	By:	/s/ Nasrat Hakim	 
	 	 	 
	Name:	Nasrat Hakim	 
	 	 	 
	Title:	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]